December 2, 2024 - 10:43

Analyst Mark Palmer has provided insights into the potential for Bitcoin to soar to $225,000, emphasizing that the cryptocurrency remains a strong investment option. Palmer highlights several factors contributing to this optimistic outlook.
Firstly, he points to the increasing institutional adoption of Bitcoin, which has gained traction over the past few years. Major financial institutions and corporations are beginning to recognize Bitcoin as a legitimate asset class, driving demand and interest among investors.
Additionally, Palmer notes the limited supply of Bitcoin, capped at 21 million coins, which creates a scarcity that could push prices higher as demand continues to grow. He also mentions the potential for Bitcoin to be viewed as a hedge against inflation, particularly in uncertain economic times.
With these factors in play, Palmer believes that Bitcoin's trajectory is poised for significant growth, making it an appealing option for both seasoned investors and newcomers to the cryptocurrency market.
May 31, 2026 - 03:22
Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200%A single investment fund has placed a staggering $143 million wager on Indivior, a pharmaceutical company whose shares have skyrocketed roughly 200% over the past year. The bold move comes as the...
May 30, 2026 - 04:48
Citizens Financial Group Links Rhode Island Training Push To Long Term StoryCitizens Financial Group has announced new community investments in Rhode Island that focus on workforce development and financial education. The company introduced a statewide Banking...
May 29, 2026 - 18:50
Was Trump's investment in a sushi restaurant a mistake? Why some financial experts say Trump’s trades smell fishyA recent investment by former President Donald Trump has sparked confusion and criticism from financial experts, who are questioning whether the move was a costly error. Trump reportedly put money...
May 29, 2026 - 00:56
VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPACSwiss biotech firm VERAXA Biotech AG has secured a significant financial commitment as it prepares to list on the Nasdaq. The company announced it has entered into a securities purchase agreement...